BioMimetic sees FDA panel detractors for bone graft system

05/12/2011 | Wall Street Journal, The

An FDA advisory panel narrowly recommended the approval of BioMimetic Therapeutics' Augment bone graft system, which is designed for use in foot and ankle fusion surgeries. Meanwhile, BioMimetic officials responded to a negative review by FDA staff, saying there "was absolutely no data" to indicate that its device causes cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT